Redefining Allogeneic Transplants & Cellular Therapy: Key Takeaways from EBMT 2025 - Episode 16
EBMT 2025: Exciting Updates and Advancements in AlloHSCT
Panelists discuss key updates from EBMT (European Society for Blood and Marrow Transplantation) 2025, including advancements in immune reconstitution, novel graft-vs-host disease (GVHD) prophylaxis strategies, and addressing ongoing unmet needs in allogeneic hematopoietic stem cell transplantation (alloHSCT), such as improved infection control, GVHD prevention, and enhancing long-term survival and quality of life.
Summary for Physicians: Key Updates in AlloHSCT from EBMT 2025
At EBMT 2025, several abstracts highlighted exciting advancements in alloHSCT, as follows:
- Immune reconstitution and viral infection control: A study presented by Politikos et al explored differential immune reconstitution with ORCA-T and CD34+ allografts, offering new insights into controlling viral infections posttransplant.
- GVHD prophylaxis: Boisclair et al introduced a calcineurin inhibitor (CNI)-free approach to GVHD prevention, focusing on novel strategies to reduce the toxicity and complications associated with CNIs.
Unmet Needs in AlloHSCT: The discussion also highlighted ongoing unmet needs in alloHSCT, including the following:
- Infection control: The need for improved strategies to prevent and manage viral and fungal infections in high-risk patients.
- GVHD prevention: Continued challenges in preventing GVHD without compromising immune function, particularly through less toxic regimens.
- Long-term outcomes: The necessity to enhance long-term survival and quality of life, addressing complications such as nonrelapse mortality, relapse rates, and posttransplant recovery.
These ongoing challenges in alloHSCT underscore the need for innovative approaches to improve patient outcomes.
Nelli Bejanyan reports consulting or advisory role for CareDx, Medexus Pharmaceuticals, Orca Biosystems, AlloVir, TScan Therapeutics, and Pfizer; and research funding from CRISPR Therapeutics. Everett Meyer reports sponsored research from Orca Biosciences, Kyverna; and a scientific advisor role and equity holder for GigaMune, Indee, TRACT, Jura Biosciences.Caspian Oliai reports no relevant disclosures (investigator on the Orca T trial funded by Orca Biosciences). Arpita P. Gandhi reports roles with OncLive, MJH Life Sciences, OrcaBio (research), CareDx (Advisory Board). Amandeep Salhotra reports received funding from Rigel, Bristol Myers Squibb and Orca Biosciences; and speakers bureau for Incyte and Sanofi.
Related Content:
